-
Exclusive: Recro Pharma CEO Talks Meloxicam Non-Opioid Product Ahead Of APS Annual Meeting
Wednesday, May 17, 2017 - 11:15am | 572Read More...Recro Pharma Inc (NASDAQ: REPH) recently announced positive Phase 3 safety data for its palliative drug, IV Meloxicam, and CEO Gerri Henwood is eager to take the non-opioid, preferential COX-2 inhibitor to the next level. The company looks to file a New Drug Application with the Food and Drug...
-
Recro Pharma Offers A Non-Opioid Alternative For Pain Management; Brean Assumes With Buy Rating
Monday, October 3, 2016 - 10:34am | 313Read More...Brean assumed coverage of Recro Pharma Inc (NASDAQ: REPH) with a Buy rating and $21 price target. The firm noted the company focuses on developing non-opioid treatments for the management of acute pain in hospital and ambulatory care settings. The firm sees IV meloxicam as addressing a market,...
